EP3 Stock Chart & Stats
€3.16
€0.02(0.58%)
At close: 4:00 PM EDT
€3.16
€0.02(0.58%)
Day’s Range― - ―
52-Week Range€1.80 - €4.00
Previous CloseN/A
Volume0.00
Average Volume (3M)109.00
Market Cap
€242.50M
Enterprise Value€169.65M
Total Cash (Recent Filing)€160.58M
Total Debt (Recent Filing)€12.09M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Nov 09, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding68,968,630
10 Day Avg. Volume0
30 Day Avg. Volume109
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.52
Price to Sales (P/S)1.55
P/FCF Ratio-3.34K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.25Price Target Upside97.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.59
Revenue Forecast (FY)€108.72M
Bulls Say, Bears Say
Bulls Say
Strong LiquidityThe combination of $161 million in cash and zero debt gives OraSure meaningful financial flexibility over the next several quarters. This liquidity can fund product launches, regulatory work, and operating needs without immediate reliance on borrowing, while reducing balance-sheet stress during the recovery.
Regulatory Product ProgressClearance of Colli-Pee for eight STI indications and authorization for Ebola 2.0 expand the company’s commercially usable product portfolio. These milestones support future revenue opportunities, strengthen OraSure’s diagnostic capabilities, and provide launch platforms beyond its existing products.
Sequential Recovery And Margin ImprovementSequential growth across the business, together with higher gross margin, indicates that recent operating actions are beginning to improve execution. Lower scrap, operational efficiencies, and recovery in Diagnostics and SMS could support a more sustainable earnings trajectory if the trend continues.
Bears Say
Severe Revenue And Profitability DeclineThe sharp TTM revenue contraction and deeply negative operating and net margins show that OraSure’s current expense base is not aligned with its reduced sales level. This weak earnings profile limits internal funding capacity and makes a durable recovery dependent on renewed demand and cost improvement.
Persistent Cash BurnSustained operating and free-cash-flow losses are a material fundamental weakness because they consume liquidity while the company remains unprofitable. Although management targets operating cash-flow breakeven entering 2027, continued burn before then could constrain investment flexibility and increase execution pressure.
IntelliQ Regulatory SetbackThe IntelliQ withdrawal removes an expected near-term product catalyst and leaves the timing of resubmission and clearance uncertain. Delayed commercialization can defer potential revenue, extend development spending, and increase dependence on Colli-Pee, Ebola 2.0, and existing products to drive recovery.
Orasure Technologies News
EP3 FAQ
What was Orasure Technologies’s price range in the past 12 months?
Orasure Technologies lowest stock price was €1.80 and its highest was €4.00 in the past 12 months.
What is Orasure Technologies’s market cap?
Orasure Technologies’s market cap is €242.50M.
When is Orasure Technologies’s upcoming earnings report date?
Orasure Technologies’s upcoming earnings report date is Nov 09, 2026 which is in 8 days.
How were Orasure Technologies’s earnings last quarter?
Orasure Technologies released its earnings results on Aug 05, 2026. The company reported €0.08 earnings per share for the quarter, beating the consensus estimate of -€0.241 by €0.321.
Is Orasure Technologies overvalued?
According to Wall Street analysts Orasure Technologies’s price is currently Undervalued.
Does Orasure Technologies pay dividends?
Orasure Technologies does not currently pay dividends.
What is Orasure Technologies’s EPS estimate?
Orasure Technologies’s EPS estimate is -0.18.
How many shares outstanding does Orasure Technologies have?
Orasure Technologies has 68,968,630 shares outstanding.
What happened to Orasure Technologies’s price movement after its last earnings report?
Orasure Technologies reported an EPS of €0.08 in its last earnings report, beating expectations of -€0.241. Following the earnings report the stock price went down -3.955%.
Which hedge fund is a major shareholder of Orasure Technologies?
Currently, no hedge funds are holding shares in DE:EP3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orasure Technologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€6.25 (97.68% Upside)
€6.25 (97.68% Upside)
Blogger Sentiment
Neutral
DE:EP3 Sentiment 100%
Sector Average 64%
Sector Average 64%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.92%
12-Months-Change
Fundamentals
Return on Equity
-14.73%
Trailing 12-Months
Asset Growth
-18.98%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Orasure Technologies
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.
EP3 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a cautiously positive picture: the company delivered sequential revenue growth (9.7%), segment recoveries (Diagnostics +14.7% and SMS +9.0% sequentially), margin expansion (+120 bps GAAP gross margin) and achieved important regulatory milestones (Colli‑Pee FDA clearance and Ebola 2.0 EUA). The primary setback is the withdrawal and delay of the IntelliQ CT/NG FDA submission, alongside a non‑GAAP operating loss ($14.7M) and negative operating cash flow (‑$9.9M) this quarter. Strong cash ($161M), zero debt, insourcing and cost discipline, and clear launch plans temper the impact of the IntelliQ delay and one‑time G&A items; management reiterates revenue growth for 2026 and expects operating cash flow breakeven entering 2027.View all DE:EP3 earnings summariesEP3 Stock 12 Month Forecast
Average Price Target
€6.25
▲(97.68% Upside)
Technical Analysis
InfuSystem Holdings
―
Stereotaxis
―
Utah Medical Products
―
Microbot Medical
―
Sanara MedTech
―








